TLT.v Message Board - Msg: 32296067

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TLT.v

TLT.V 0.160

+3.2%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: 3bar who wrote (1354)	8/23/2019 9:42:43 AM
From: 3bar	of 1869

We might be there ? @Enriquesuave Old generation PDT yielded about 60-90% CR at 12 months, both that was Photofrin and Radachlorin respectively. Good but was IV administered and poor Dosimetry thus many more side effects and less safety even though best CR rates. TLD-1433 was deeemed 192 times as safe and effective vs Photofrin. With virtually No side effects and safe, as drug is much more tumour selective ( 192 times) vs old drugs. Optimised Dosimetry allows for consistently maximizing safety and efficacy for a personalized treatment. So I expect between 60-90% CR. Can they beat that or be closer to 90%? Yes a verygood chance IMO, but anything really well above the 30% which is the minimum FDA is ideally looking for will be a winner. If we hit over 65-70%, then we have statistical evidence to replace Cystectomy which is the Gold Standard for those who failed BCG. That would mean that instead of recommending Cystectomies, they would recommend TLD-1433 PDT. IMHO 2019.cua.events might be there ?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next